Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with
trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.